Chonnam Med J.
2000 Sep;36(3):239-244.
Clinical Effects of Cerivastatin (Lipobay?) in Patients with Primary Hypercholesterolemia
- Affiliations
-
- 1Division of Cardiology, Heart Center, Chonnam National University Hospital.
- 2Department of Anatomical Pathology, Chonnam National University Hospital.
- 3Department of Nuclear Medicine, Chonnam National University Hospital.
Abstract
-
BACKGROUND: Many previous studies have shown that hypercholesterolemia, particularly high LDL- cholesterol is the main cause of atherosclerosis and coronary artery disease. HMG-CoA reductase inhibitor has been used for a decade to lower LDL cholesterol levels and to improve clinical outcomes of coronary artery disease. This study was aimed to evaluate the clinical efficacy and safety profile of cerivastatin, a new HMG-CoA reductase inhibitor.
METHOD: Thirty-two patients (male : female = 16 : 16, mean age 51.9) with hypercholesterolemia (12- hour fasting serum LDL-cholesterol: 145 - 250 mg/dL, serum triglyceride: <400 mg/dL) were enrolled for diet therapy for 4 weeks. After 4 weeks of diet therapy, serum lipid profile was reevaluated and patients with LDL-cholesterol >130 mg/dL were assigned to receive cerivastatin 0.3 mg per day for 8 weeks. Serum AST, ALT and creatine kinase were also followed in addition to blood chemistry tests for lipid profiles at 8 weeks for safety assessment.
RESULT: Thirty-two enrolled patients were eligible to analysis. Serum levels of total cholesterol, triglyceride, LDL-cholesterol, apolipoprotein B were significantly reduced by 16.4%, 17.6%, 16.8% and 17.0%, respectively 8 weeks after cerivastatin medication. The target level of LDL-cholesterol (<130 mg/dL) was achieved in 87% of the cases and no serious side effects developed.
CONCLUSION
These results suggest that cerivastatin is effective and safe in the treatment of hypercholesterolemia.